NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/03/2026
Voltar para busca
Dado oficial do USPTO
TIZUREST
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
58
Atualização mais recente
03/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
06/11/2020
Data de registro
03/03/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/03/2026
Última transação
03/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Shanghai, CN
Examinador
POWERS, ALEXANDER L
Unidade examinadora
L10
Localização atual
INTENT TO USE SECTION
Titulares e representantes
Titulares
EVIVE BIOTECHNOLOGY (SHANGHAI) LTD.
EVIVE BIOTECHNOLOGY (SHANGHAI) LTD.
Generon (Shanghai) Corporation Ltd.
Representantes
Muzamil Huq MORRISON & FOERSTER LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Chemical pharmaceutical preparations in the nature of chemical preparations for pharmaceutical purposes for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; human medicines for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; biochemical drugs for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; pharmaceutical preparations for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medicinal capsules for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical chemical preparations in the nature of chemical preparations for medical purposes for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical biological preparations for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical ointmentsmedicated ointments for treating or preventing inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical drugs for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical diagnostic preparations
Publicações
Histórico de despachos e eventos da marca no USPTO.
58 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
03/03/2026
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
09/02/2026
IUCN
NOTICE OF ALLOWANCE CANCELLED
06/02/2026
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
06/02/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
23/12/2025
EX5G
SOU EXTENSION 5 GRANTED
22/12/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
22/12/2025
EXT5
SOU EXTENSION 5 FILED
04/08/2025
EEXT
SOU TEAS EXTENSION RECEIVED
04/08/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/02/2025
EX4G
SOU EXTENSION 4 GRANTED
01/02/2025
EXT4
SOU EXTENSION 4 FILED
31/01/2025
EEXT
SOU TEAS EXTENSION RECEIVED
31/01/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
24/07/2024
EX3G
SOU EXTENSION 3 GRANTED
23/07/2024
EXT3
SOU EXTENSION 3 FILED
23/07/2024
EEXT
SOU TEAS EXTENSION RECEIVED
22/07/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/02/2024
EX2G
SOU EXTENSION 2 GRANTED
05/02/2024
EXT2
SOU EXTENSION 2 FILED
05/02/2024
EEXT
SOU TEAS EXTENSION RECEIVED
05/02/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
22/01/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
22/01/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
22/01/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/01/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/01/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/01/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/08/2023
EX1G
SOU EXTENSION 1 GRANTED
07/08/2023
EXT1
SOU EXTENSION 1 FILED
07/08/2023
EEXT
SOU TEAS EXTENSION RECEIVED
07/08/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/12/2022
PUBO
PUBLISHED FOR OPPOSITION
13/12/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/11/2022
ALIE
ASSIGNED TO LIE
08/11/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
26/09/2022
DOCK
ASSIGNED TO EXAMINER
31/05/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
20/04/2022
GNSI
INQUIRY TO SUSPENSION E-MAILED
20/04/2022
CNSI
SUSPENSION INQUIRY WRITTEN
20/04/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/10/2021
GNSL
LETTER OF SUSPENSION E-MAILED
04/10/2021
CNSL
SUSPENSION LETTER WRITTEN
04/10/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/10/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/09/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/09/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
16/06/2021
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
16/04/2021
GPRA
PRIORITY ACTION E-MAILED
16/04/2021
CPRA
PRIORITY ACTION WRITTEN
16/04/2021
DOCK
ASSIGNED TO EXAMINER
14/04/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/01/2021
NWAP
NEW APPLICATION ENTERED
10/11/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TIZUREST ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.